DUBLIN, Aug. 28, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/zsgg5n/global_and_usa) has announced the addition of the "Global & USA BioSimilar Market Analysis to 2021" report to their offering.
The highly awaited US Biosimilar market will be initiated in September as Sandoz launches its highly awaited filigrastim biologic, Zarxio. How will the global market react? Will biosimilars explode into the biologics market? The author reveals that biosimilars could save the US economy up to $250 billion within the next seven years. A newly published Global and USA Biosimilar Market Analysis to 2021 indicates that there is tremendous interest by big pharma and generics companies in this industry who are focusing on biosimilar development of Avastin, Enbrel, Herceptin, Humira and Rituxan.
Global Biosimilar Market
While the U.S. has approved only one biosimilar therapeutic; Japan, Australia and Europe have approved six, eight and 19 biosimilars respectively. Already, biosimilars have an exemplary safety track record in the E.U., Japan, and Canada where biosimilars are regularly competing against biologics for nearly seven years. The E.U. was the first geographic market to develop the process of authorization of biosimilars, setting an example for many other developing markets to follow suit. As of 2015, the E.U. has approved 19 biosimilars, out of 21 submissions, mostly for three reference biologics such as Somatropin, Epoetin alfa and Filgrastim.
Biosimilars generated revenues of $1.1 million in 2007 and gradually rose to $86.9 million in 2014. During this period, the market penetration of biosimilars in Europe and emerging markets was only about 8%. The top five biologics targeted most by biosimilar developers are Avastin, Enbrel, Herceptin, Humira and Rituxan, which together generate revenues of about $50 billion annually.
Like most other markets, a competitive biologics market can offer benefits to consumers by lowering prices and enhancing quality. In addition, biosimilars have an unblemished safety track record in the E.U., where biosimilars have been competing against biologics since 2006. Biosimilars have also proved to have a notable impact on drug prices. In the E.U., where biosimilars are already competing with biologics, biosimilars are sold at a 30% discount compared to branded biologic drugs. In spite of the approval of 21 biosimilars in Europe, only 18% of the physicians are aware of these similar versions of biologics.
US Biosimilar Market
With the approval of the first biosimilar in the U.S in early 2015 and the expected patent expiration of 12 biologics by 2020, biosimilars are expected to competitively penetrate the biologic's market. Biosimilars have thus become a threat and opportunity for biotechnology and pharmaceutical sectors. Zarxio (Filgrastim, Sandoz) will be launched into the U.S. market in September 2015 and will compete with Neupogen (Amgen) within the US G-CSF market.
Biosimilars will account for 4% to 10% of the biologics market total by 2020, depending on the number of biosimilars launched in the U.S. The U.S. is the largest market for biologics and the biosimilars can achieve 10% of the global sales in 2020, only if the volume growth for biologics is achieved in the U.S. market. The main players looking to penetrate the US biosimilar market are currently Amgen, Mylan, Pfizer, Sandoz and Hospira.
Companies Mentioned - Partial List
- AET BioTech
- Amega Biotech
- Anhui Anke Biotechnology (Group) Co., Ltd.
- Avesthagen Ltd.
- Baxter International Inc.
- Beijing Four Rings Biopharmaceutical Co., Ltd.
- Bharat Biotech International Ltd.
- Binovis SA
- BioXpress Therapeutics SA
- Biocon Ltd.
- Biogen Inc.
- Biopartners GmbH
- Biosidus SA
- Biotechnol AS
- Bioton Spolka AKcyjna
- Bioviz Technologies Pvt, Ltd.
- Boehringer Ingelheim GmbH
- Bolder BioTechnology Inc.
- CJSC Biocad
- CT Arzneimittel GmbH
- Cadilla Pharmaceuticals Ltd.
- Celltrion Inc.
- Cerbios-Pharma SA
- Cipla Ltd.
For more information visit http://www.researchandmarkets.com/research/zsgg5n/global_and_usa
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets